Lv71
4955 积分 2021-02-06 加入
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy
1天前
已完结
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
1天前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
2天前
已完结
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
3天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
12天前
已完结
Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECIST
17天前
已完结
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
25天前
已完结
SKYSCRAPER-07: Falling Short of the Top
1个月前
已完结
Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers
1个月前
已完结
Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review
1个月前
已完结
皖公网安备34019202002308
